Renal Cell Carcinoma
Systemic therapy for mRCC: second line and beyond

Louisa (60 years old)

Louisa, 60 years old, works as an accounting consultant in a local company.

  • Diagnosed with metastatic ccRCC (2 lesions in the lung, 1 in liver), PD-L1 positive
  • Started pembrolizumab + axitinib combination therapy 3 years ago
  • She completed 2 years / 35 cycles of pembrolizumab 1 year ago, with a partial response to this regimen (only 1 metastatic lesion remains, in the lung). She is continuing on axitinib monotherapy

Now, 1 year after stopping pembrolizumab, she presents with a new metastatic site in the liver.

Which treatment option would you choose for this patient?